Biotech Values

[jq1234]

All told, EXEL strikes me as a company that’s desperately and prematurely trying to sell XL184 to the investment community as a cancer drug with Avastin-like upside. That could conceivably happen, but the odds are very much against it.

It depends on where you came from. I didn't get the impression they were trying to sell XL184 as a cancer drug with Avastin-like upside. XL184 was left to be dead after BMY walked, and now the RDT data showed great promise. I had low to moderate expectation on XL184 before RDT result. If I had worked on this study, I would be excited as well. Compare XL184 data in CRPC with Provenge and Abiraterone at the same stage, I like XL184's chance. The former showed almost no change to measurable disease, the later showed significantly reduction of PSA.

By the way, I don't even hold EXEL shares right now.